P016 Showdowns in Pediatric Dermatology: Current Controversies from the Pediatric Dermatology Research Alliance
DESCRIPTION
The goal of this session is to bring novel but controversial topics in pediatric dermatology to the main stage by bringing together experts from the Pediatric Dermatology Research Alliance (PeDRA)! The target audience are dermatologists, especially those who see pediatric patients. During this session, 3 hot-off-the-press but controversial topics will be presented to the audience as live panel debates with at least one discussant for and one discussant against a particular topic. We will bring together experts in the field on the controversy at hand and through lively discussion, present the most up to date evidence differing opinions.
LEARNING OBJECTIVES
Examine novel and groundbreaking topics in pediatric dermatology and pediatric dermatology research
Compare and contrast alternative perspectives in controversial topics 1. systemic JAKi as 1st line for children with vitiligo 2. TNFa inhibitors, cyclopsorine, prednisone, or IVIG for children with SJS/TEN 3. Novel vs traditional topicals for the treatment of atopic dermatitis
Evaluate and summarize the evidence presented and formulate his or her own opinions
SCHEDULE
8:00 PM
Introduction
JiaDe Yu, MD, FAAD
8:10 PM
Should you use a systemic JAKi as 1st line systemic therapy for children with vitiligo?
Ammar M. Ahmed, MD, FAAD, Anna Cristina Garza-Mayers, MD, PhD, FAAD
8:40 PM
Drug or Bug? Blistering Reactions in Kids
Markus Boos, PhD, MD, FAAD, Michele Ramien, MD, FAAD
9:10 PM
Oldie but a goodie? Novel vs traditional therapies for the treatment of atopic dermatitis in children (focus on topicals)
JiaDe Yu, MD, FAAD, Thy Nhat Huynh, MD, FAAD
9:40 PM
Q&A
SPEAKERS
Ammar M. Ahmed, MD, FAAD
Dell Medical School at the University of Texas at Austin
Markus Boos, PhD, MD, FAAD
Anna Cristina Garza-Mayers, MD, PhD, FAAD
Thy Nhat Huynh, MD, FAAD
Michele Ramien, MD, FAAD
Alberta Children's Hospital, University of Calgary
JiaDe Yu, MD, FAAD
Massachusetts General Hospital/Harvard Medical School
HANDOUTS
SPEAKER DISCLOSURES
Ammar M. Ahmed, MD, FAAD
Avita Medical – Advisory Board(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Markus Boos, PhD, MD, FAAD
Regeneron Pharmaceuticals, Inc. – Investigator(No Compensation Received);
Anna Cristina Garza-Mayers, MD, PhD, FAAD
Sanofi/Regeneron – Advisory Board(Honoraria);
Thy Nhat Huynh, MD, FAAD
No financial relationships exist with ineligible companies.
Michele Ramien, MD, FAAD
Eli Lilly – Consultant (1099 relationship)(Honoraria); Leo Pharma Inc – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding), Speaker(Honoraria);
JiaDe Yu, MD, FAAD
American Contact Dermatitis Society – Board of Directors(No Compensation Received); Arcutis Biotherapeutics – Advisory Board(Honoraria); Dermavant Sciences – Speaker/Faculty Education(Honoraria); Incyte – Advisory Board(Honoraria); L'Oreal – Consultant (1099 relationship)(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Speaker(Honoraria); Leo Pharma – Advisory Board(Honoraria); National Eczema Association – Consultant(Fees), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria);